Melphalan

Melphalan is a strong medicine used to treat certain types of cancer. It works by killing cancer cells. It can affect the bone marrow, so doctors need to monitor blood counts carefully.

Brand names:Alkeran
Medication

What people taking Melphalan report

Every report comes from a Lived member, sent anonymously.

Have you tried Melphalan for Multiple Myeloma?

NameHow it went

About Melphalan

What It's For

Melphalan is a chemotherapy drug used mainly for multiple myeloma, a cancer of plasma cells in the bone marrow. Its most common use today is as a high-dose treatment given a few days before an autologous stem cell transplant, in which a person's own previously collected stem cells are returned to rebuild the bone marrow. European myeloma guidelines name high-dose melphalan as the standard preparation (called conditioning) for this transplant in fit adults with newly diagnosed myeloma. Evomela is a brand of IV melphalan approved for this purpose. At lower doses, IV melphalan, including generic melphalan hydrochloride for injection and the brand Ivra, is approved to control myeloma in people who cannot take it by mouth. Melphalan is also part of some combination treatments for people who are not transplant candidates, such as bortezomib (a targeted myeloma drug), melphalan and the steroid prednisone. A separate product, the Hepzato Kit, delivers melphalan directly into the liver's blood supply for adults with uveal melanoma (a cancer of the eye) that has spread to the liver and cannot be removed with surgery. Melphalan was long sold as Alkeran tablets and injection, and the tablets were also used for a type of ovarian cancer. The FDA now lists the Alkeran products and US melphalan tablets as discontinued, so current US use is almost entirely by vein or, for Hepzato, into the liver's artery.

How It Works

Melphalan belongs to a group of chemotherapy drugs called alkylating agents. It attaches to DNA and links its two strands together, so a cell can no longer copy its DNA properly, and the damaged cell dies. Unlike some chemotherapy drugs that mainly affect cells that are actively dividing, melphalan also damages cells that are resting. The same action explains its main harms. Bone marrow, where blood cells are made, is very sensitive, so blood counts fall after each dose. At the doses used before transplant, the marrow is deliberately wiped out along with as many myeloma cells as possible, which is why the person's stored stem cells are infused afterward to restart blood production. DNA damage in healthy cells is also why melphalan carries a small long-term risk of a second cancer.

Dosage & Administration

Melphalan is given by trained staff in a hospital or cancer center, not taken at home. Doses are based on body size, measured as body surface area in square meters (written mg/m²), and are adjusted for blood counts and kidney function. For transplant conditioning, the standard total dose is 200 mg/m². With Evomela, half is infused over about 30 minutes on each of two consecutive days, ending two days before the stem cells are returned. Anti-nausea medicine is given beforehand. For longer-term control of myeloma, IV melphalan is usually given as a 15 to 20 minute infusion every two weeks for four doses, then every four weeks once blood counts have recovered. Counts are checked before every dose, and the dose is lowered or delayed when they are too low. The infusion goes into a fast-running IV line or a central line (a catheter in a large vein) because melphalan can damage the surrounding tissue if it leaks out of the vein. Pain, burning, redness or swelling at the IV site during an infusion should be reported to the nurse at once. People with reduced kidney function clear melphalan more slowly and have deeper drops in blood counts, so their dose is often reduced. Hepzato is given differently: it is infused into the hepatic artery, the main artery to the liver, during a catheter procedure, usually every 6 to 8 weeks for up to six treatments.

Side Effects

Nausea, diarrhea and tiredness affect nearly everyone in the days after high-dose melphalan, and most people also vomit. Loss of appetite, changes in taste, constipation, fever and low potassium or phosphate levels are common. Painful sores in the mouth and throat (mucositis) can make eating and swallowing difficult; about one in eight people in the Evomela study had severe mucositis, which is managed with pain medicine and nutritional support. Hair loss can also occur. Lower-dose treatment causes milder versions of these effects. The most important effect is on blood counts. After conditioning, white cells, red cells and platelets fall to very low levels, typically about a week after dosing, and in the Evomela study they began to recover a median of 12 to 13 days after the stem cells were returned. During that window, infection and bleeding are the main dangers, so antibiotics and transfusions are common. Fever, chills, a sore throat or new cough, unusual bruising or bleeding, black or bloody stools, or vomiting blood need a call to the care team right away, using the after-hours number they provide. Infection can become serious quickly when white cells are low. Yellowing of the skin or eyes, pain under the right ribs or dark urine can signal liver injury, including a rare blockage of small veins in the liver (veno-occlusive disease), and should also be reported promptly.

Interactions & Warnings

Melphalan carries a boxed warning, the FDA's most prominent caution, covering three risks. The first is severe bone marrow suppression, described above. The second is allergic reaction: about 2% of people given IV melphalan have one, sometimes severe (anaphylaxis), usually after several courses. Hives, itching, facial swelling, wheezing, trouble breathing or lightheadedness during an infusion should be reported to staff immediately so they can stop it and treat the reaction. Anyone who has had a serious allergic reaction to melphalan should not receive it again in any form. The third is a second cancer. Melphalan can lead, sometimes years later, to acute leukemia or related bone marrow disorders. The risk rises with the total amount received over time: in one study of long-term melphalan tablets, the 10-year risk was under 2% at lower cumulative doses but about 1 in 5 at very high cumulative doses. Melphalan can seriously harm a developing baby. Women who could become pregnant should use effective contraception during treatment and for 6 months after the last dose, and men with partners who could become pregnant should do so for 3 months. Breastfeeding is not recommended during treatment and for one week afterward. Melphalan can also stop ovarian function, leaving some women without periods permanently, and can reduce sperm production, sometimes permanently. Severe kidney failure has been reported when high-dose melphalan was followed by cyclosporine, an immune-suppressing drug, and IV melphalan may make lung damage from carmustine (BCNU), another chemotherapy drug, more likely. Live vaccines should be avoided while the immune system is suppressed, and the care team should know about every medicine and supplement being taken. Hepzato has its own boxed warning. The liver procedure can cause serious bleeding, liver injury and blood clots, so people are watched closely during it and for at least 72 hours afterward. It is available only at certified centers under a restricted FDA safety program, and blood thinners and some blood pressure medicines are stopped beforehand.

What to Expect

For a transplant, melphalan is one step in a longer plan. People first receive several months of initial myeloma treatment, then have stem cells collected and frozen. Melphalan is given just before the stem cells are returned, and close monitoring, in hospital or with frequent clinic visits, continues until blood counts recover. Most side effects ease as counts come back, but recovery is gradual. The team usually assesses response about three months after transplant using blood and urine myeloma markers. In the Evomela study, the share of people with at least a partial response rose from 79% before transplant to 95% at about three months. In a large trial, adding high-dose melphalan and transplant to modern drug treatment lengthened the typical time before myeloma progressed from about 36 to 50 months, although survival at four years was similar. Guidelines then recommend maintenance treatment, most often with lenalidomide, an oral myeloma drug, to keep the disease under control longer. With lower-dose IV treatment, improvement builds slowly over months, and about one-third to one-half of people with myeloma respond. With Hepzato, about a third of people in the main study had their liver tumors shrink, and those responses lasted a median of about 14 months. After any form of melphalan, follow-up blood tests continue, partly to watch for late effects such as a second cancer.

Questions to Ask Your Doctor

  1. 1.What would high-dose melphalan with a stem cell transplant add for me compared with continuing other myeloma treatment?
  2. 2.How will my kidney function, age or other conditions affect my dose and my risks?
  3. 3.What should I do if I develop a fever while my counts are low, and how do I reach the team after hours?
  4. 4.How could melphalan affect my fertility, and should I consider preserving eggs or sperm before treatment?
  5. 5.How large is my risk of a second cancer, and how will we watch for it over the years?

Last reviewed • Oct 2026

Educational content, not medical advice.